EBC-46
Fontainea picrosperma grows wild only in north Queensland's rainforests, but controlled indoor cultivation has succeeded in Australia and Asia — here is what growers have discovered.
EBC-46
EBC-46's ability to convert immunologically cold tumours into hot ones makes it a compelling partner for checkpoint blockade — here is the biology and the trial rationale.
EBC-46
EBC-46 targets PKC isoforms that regulate mitochondrial function and energy metabolism — a biological dimension that extends the compound's relevance well beyond oncology.
EBC-46
Expanded access programmes offer a potential pathway for cancer patients to receive tigilanol tiglate outside clinical trials — here is how the regulatory process works.
EBC-46
Independently collected accounts from verified blushwood extract users reveal a consistent pattern of inflammation reduction, improved energy, and systemic wellbeing changes — a signal the research community should investigate.
EBC-46
EBC-46 lights the immune fire with acute local tumour antigen release. Checkpoint inhibitors remove the suppressors trying to extinguish it. The combination rationale is mechanistically sound.
EBC-46
The same PKC isoforms EBC-46 activates for anti-tumour effect also regulate mitochondrial membrane dynamics and cellular energy production — a scientifically rich area still awaiting systematic study.
EBC-46
Fontainea picrosperma is native to a narrow strip of Far North Queensland rainforest, but dedicated cultivators in indoor environments have successfully grown it far beyond those boundaries.
EBC-46
Drugs injected directly into tumours operate under different regulatory logic than systemic therapies. Here is how EBC-46 is navigating — and reshaping — that framework.
EBC-46
From a post-sepsis patient whose doctor attributed blood-clot resolution to blushwood extract, to a stage 4 cancer case with positive scans — these verified reports demand formal scientific investigation.
EBC-46
The Blushwood tree grows wild only in north Queensland's rainforest, but controlled cultivation has proven viable across Australia and Asia — opening the door to scalable, sustainable supply of tigilanol tiglate.
EBC-46
The first-in-human Phase I trial of tigilanol tiglate demonstrated localised anti-tumour responses with a clean systemic safety profile — a result that immediately distinguished EBC-46 from prior PKC-targeting drugs.